Video

Examining Stress and Quality of Life in Bladder Cancer

Author(s):

Ahrang Jung

Patients with non-muscle invasive bladder cancer experience high levels of distress, according to one study.

Patients with non-muscle invasive bladder cancer have high levels of distress and post-traumatic stress disorder (PTSD) symptoms, according to research conducted by Ahrang Jung, a Ph.D., student at the University of North Carolina at Chapel Hill School of Nursing.

In her study, Jung found that about one if four patients with the disease experience PTSD symptoms. Factors that contribute to their stress include uncertainty for the future, especially when it comes to cancer recurrence, as well as frequently needed to undergo invasive testing.

Related Videos
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of woman.
Image of woman.
Image of woman.
Image of man wearing baseball cap backwards.
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image od grey haired Doctor.
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
Related Content
The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in muscle invasive bladder cancer.
March 28th 2025

FDA Approves Imfinzi Therapy in Muscle Invasive Bladder Cancer

Ryan Scott
The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in muscle invasive bladder cancer.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Padcev plus Keytruda elicited responses in the first-line setting, with Padcev showing benefit in later lines, in metastatic urothelial carcinoma: © freshidea - stock.adobe.com.
March 22nd 2025

Padcev With or Without Keytruda Elicits Responses in Urothelial Cancer

Alex Biese
In metastatic urothelial carcinoma, Padcev plus Keytruda elicited responses in the first-line setting, with Padcev showing benefit in later lines.
cancer horizons podcast logo
December 20th 2023

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Illustration of bladder cancer.
March 14th 2025

Blue Light Cystoscopy Reduces Recurrence in High-Risk Bladder Cancer

Ryan Scott
Blue light cystoscopy had a statistically significant reduction in risk of recurrence versus white light cystoscopy in high-risk bladder cancer.
Illustration of bladder.
March 13th 2025

Antihistamines Associated With Bladder Cancer Survival, Progression Improvements

Alex Biese
Antihistamines are associated with improvement for patients with metastatic urothelial carcinoma receiving Tecentriq.